Watts, J., Borate, U., Levis, M., Abaza, Y., Wang, E., Zeidner, J., Cai, H., Xu, B., Robson, P., Watanabe, A., Hitron, M., Shah, J., Kantarjian, H., Daver, N. (2025). Preliminary data from the ongoing Phase 1 study of the menin-MLL inhibitor enzomenib (DSP-5336) in combination with venetoclax and azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia. Blood. https://doi.org/10.1182/blood-2025-765